Novartis gene therapy for fatal childhood disease delivers strong sales during fourth quarter
Zolgensma, the Novartis gene therapy for infants and the world’s most expensive medicine, continues to perform well commercially, bringing in $186 million during the fourth quarter, topping analyst expectations on Wednesday.
Last June, Novartis secured U.S. approval for Zolgensma as a one-time treatment for spinal muscular atrophy, a rare and deadly neurological disease. It carries a record price tag of $2.1 million, or an annualized cost of $425,000 per year for five years.
